Za­vante hits the fin­ish line, de­clar­ing a piv­otal win for its an­tibi­ot­ic now head­ed (even­tu­al­ly) to the FDA

Za­vante CEO Ted Schroed­er

The team at Za­vante Ther­a­peu­tics had a very sim­ple goal.

Armed with $45 mil­lion in in­vestor back­ing, they took a broad spec­trum an­tibi­ot­ic that’s been used in var­i­ous coun­tries around the world — out­side the US — and put it through a late-stage, head-to-head, non-in­fe­ri­or­i­ty tri­al against a com­bo an­tibi­ot­ic that’s al­ready in use in the US.

And they are claim­ing a win, prep­ping an FDA ap­pli­ca­tion now for a new an­tibi­ot­ic in an in­creas­ing­ly drug-re­sis­tant world as they con­sid­er their op­tions: mar­ket­ing it them­selves or sell­ing it to a play­er in the field.

By the time they get through the NDA process, CEO Ted Schroed­er tells me, they will have spent “every nick­el” of their $45 mil­lion.

In­ves­ti­ga­tors re­cruit­ed 465 pa­tients, giv­ing their an­tibi­ot­ic Zolyd (fos­fomycin for in­jec­tion, or ZTI-01) in 1-hour IV in­fu­sions three times a day ver­sus a some­what small­er dose of IV piperacillin (peni­cillin)/tazobac­tam at the same sched­ule.

Here is the bot­tom line, pre­sent­ed by Za­vante:

In the study, ZOLYD met the pri­ma­ry end­point of sta­tis­ti­cal non-in­fe­ri­or­i­ty com­pared to piperacillin/tazobac­tam, with an over­all suc­cess rate of 64.7% (119/184 pa­tients) ver­sus 54.5% (97/178 pa­tients), re­spec­tive­ly, a treat­ment dif­fer­ence of 10.2% (95% CI: -0.4, 20.8). Clin­i­cal cure rates were high and sim­i­lar be­tween treat­ment groups (90.8% vs. 91.6%, re­spec­tive­ly).

Fos­fomycin was launched in Spain and then start­ed mak­ing the rounds un­til Big Phar­ma in­tro­duced new class­es of an­tibi­otics and ba­si­cal­ly de­clared the prob­lem of an­tibi­ot­ic de­vel­op­ment fixed, says Schroed­er, a long­time biotech ex­ec with a lengthy stint at Elan on the re­sume. Then those main­stream an­tibi­otics dom­i­nat­ed the mar­ket un­til drug re­sis­tance be­gan to be­come a se­ri­ous threat. And fos­fomycin be­gan to make a come­back, at­tract­ing his at­ten­tion as a like­ly can­di­date for a first-US ap­proval.

The key, he adds, was the pas­sage of the GAIN Act, which gives this an­tibi­ot­ic a shot at eight years of mar­ket ex­clu­siv­i­ty.

Schroed­er says he and his team have the ex­pe­ri­ence to field this an­tibi­ot­ic them­selves. Or they might sell it, as seems the most like­ly suc­cess­ful out­come. An ap­pli­ca­tion will have to wait un­til H1 2018, so they can fin­ish the work.

It’s a big mar­ket, says Schroed­er, but it’s al­so a mar­ket dom­i­nat­ed by cheap, old an­tibi­otics. Schroed­er, though, feels that his an­tibi­ot­ic could come in­to fre­quent play as a com­bo, tied to oth­er an­tibi­otics as in­ten­sive care physi­cians look for a knock­out blow against in­fec­tions.

“I do think its a re­al­ly in­ter­est­ing op­por­tu­ni­ty to bring such a use­ful prod­uct for­ward in such an ef­fi­cient way,” says the CEO. Now he has to com­plete the process.

“In an en­vi­ron­ment of rapid­ly in­creas­ing re­sis­tance, safe and ef­fec­tive an­tibi­otics with ac­tiv­i­ty against MDR pathogens are sore­ly need­ed,” said Kei­th Kaye, Pro­fes­sor of Med­i­cine, Uni­ver­si­ty of Michi­gan. “If ap­proved, ZOLYD’s unique mech­a­nism of ac­tion and broad spec­trum of ac­tiv­i­ty would add to the treat­ment ar­ma­men­tar­i­um when treat­ing se­ri­ous­ly ill pa­tients in the hos­pi­tal.”

Here comes the oral GLP-1 drug for di­a­betes — but No­vo Nordisk is­n't dis­clos­ing Ry­bel­sus price just yet

Novo Nordisk’s priority review voucher on oral semaglutide has paid off. The FDA approval for the GLP-1 drug hit late Friday morning, around six months after the NDA filing.

Rybelsus will be the first GLP-1 pill to enter the type 2 diabetes market — a compelling offering that analysts have pegged as a blockbuster drug with sales estimates ranging from $2 billion to $5 billion.

Ozempic, the once-weekly injectable formulation of semaglutide, brought in around $552 million (DKK 3.75 billion) in the first half of 2019.

As Nas­daq en­rolls the fi­nal batch of 2019 IPOs, how have the num­bers com­pared to past years?

IGM Biosciences’ upsized IPO haul, coming after SpringWorks’ sizable public debut, has revved up some momentum for the last rush of biotech IPOs in 2019.

With 39 new listings on the books and roughly two more months to go before winding down, Nasdaq’s head of healthcare listings Jordan Saxe sees the exchange marking 50 to 60 biopharma IPOs for the year.

“December 15 is usually the last possible day that companies will price,” he said, as companies get ready for business talks at the annual JP Morgan Healthcare Conference in January.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 60,200+ biopharma pros reading Endpoints daily — and it's free.

A fa­vorite in Alex­ion’s C-suite is leav­ing, and some mighty sur­prised an­a­lysts aren’t the least bit hap­py about it

Analysts hate to lose a biotech CFO they’ve come to trust and admire — especially if they’re being blindsided by a surprise exit.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 60,200+ biopharma pros reading Endpoints daily — and it's free.

Oxitec biologist releases genetically modified mosquitoes in Piracicaba, Brazil in 2016 [credit: Getty Images]

In­trex­on unit push­es back against claims its GM mos­qui­toes are mak­ing dis­ease-friend­ly mu­tants

When the hysteria of Zika transmission sprang into the American zeitgeist a few years ago, UK-based Oxitec was already field-testing its male Aedes aegypti mosquito, crafted to possess a gene engineered to obliterate its progeny long before maturation.

But when a group of independent scientists evaluated the impact of the release of these genetically-modified mosquitoes in a trial conducted by Oxitec in Brazil between 2013 and 2015, they found that some of the offspring had managed to survive — prompting them to speculate what impact the survivors could have on disease transmission and/or insecticide resistance.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 60,200+ biopharma pros reading Endpoints daily — and it's free.

[via AP Images]

Pur­due threat­ens to walk away from set­tle­ment, asks to pay em­ploy­ees mil­lions in bonus­es

There are two updates on the lawsuit against Purdue Pharma over its role in fueling the opioid epidemic, as the Sackler family threatens to walk away from their pledge to pay out $3 billion if a bankruptcy judge does not stop outstanding state lawsuits against them. At the same time, the company has asked permission to pay millions in bonuses to select employees.

Purdue filed for chapter 11 bankruptcy this week as part of its signed resolution to over 2,000 lawsuits. The deal would see the Sackler family that owns Purdue give $3 billion from their personal wealth and the company turned into a trust committed to curbing and reversing overdoses.

Aerial view of Genentech's campus in South San Francisco [Credit: Getty]

Genen­tech sub­mits a big plan to ex­pand its South San Fran­cis­co foot­print

The sign is still there, a quaint reminder of whitewashed concrete not 5 miles from Genentech’s sprawling, chrome-and-glass campus: South Francisco The Industrial City. 

The city keeps the old sign, first erected in 1923, as a tourist site and a kind of civic memento to the days it packed meat, milled lumber and burned enough steel to earn the moniker “Smokestack of the Peninsula.” But the real indication of where you are and how much has changed both in San Francisco and in the global economy since a couple researchers and investors rented out an empty warehouse 40 years ago comes in a far smaller blue sign, resembling a Rotary Club post, off the highway: South San Francisco, The Birthplace of Biotech.

While No­var­tis ban­ish­es Zol­gens­ma scan­dal scars — Bio­gen goes on a Spin­raza 'of­fen­sive'

While Novartis painstakingly works to mop up the stench of the data manipulation scandal associated with its expensive gene therapy for spinal muscular atrophy (SMA) Zolgensma— rival Biogen is attempting to expand the use of its SMA therapy, Spinraza. 

The US drugmaker $BIIB secured US approval for Spinraza for use in the often fatal genetic disease in 2016. The approval covered a broad range of patients with infantile-onset (most likely to develop Type 1) SMA. 

Jason Kelly. Mike Blake/Reuters via Adobe

Eye­ing big ther­a­peu­tic push, Gink­go bags $290M to build a cell pro­gram­ming em­pire

Ginkgo Bioworks is on a roll. Days after publicizing a plan to nurture new startups via partnerships with accelerators Y Combinator and Petri, the Boston biotech says it has raised another $290 million for its cell programming platform to reach further and wider.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 60,200+ biopharma pros reading Endpoints daily — and it's free.

UP­DAT­ED: Speak­er Nan­cy Pelosi to un­veil bill for fed­er­al­ly ne­go­ti­at­ed drug prices

After months of buzz from both sides of the aisle, Speaker Nancy Pelosi will today introduce her plan to allow the federal government to negotiate prices for 250 prescription drugs, setting up a showdown with a pharmaceutical industry working overtime to prevent it.

The need to limit drug prices is a rare point of agreement between President Trump and Democrats, although the president has yet to comment on the proposal and will likely face pressure to back a more conservative option or no bill at all. Republican Senator Chuck Grassley is reportedly lobbying his fellow party members on a more modest proposal he negotiated with Democratic Senator Ron Wyden in July.